Novartis revenues 2007-2022

In 2022, the Swiss pharmaceutical company Novartis AG’s total revenue amounted to 50.5 billion U.S. dollars. This is a decrease of more than one billion U.S. dollars compared to the year before.

Novartis’ revenue by segment

Between 2014 and 2022, the multinational corporation, based in Basel, Switzerland, generated the bulk of its revenue through brand name pharmaceuticals (innovative medicines): in 2022, the company made 41.3 billion U.S. dollars from this segment. In the same year Novartis generated close to one fifth of its revenue from its generic drug division (Sandoz).

Competitor Sanofi

Another global leader in the world of healthcare and pharmaceuticals is Sanofi, which is based in Paris, France. In 2021, the French company generated 37.8 billion euros' worth of revenue. That same year, the majority of Sanofi’s revenue was earned through pharmaceuticals (27 billion euros), while the vaccine business segment generated 6.3 billion euros.

Novartis AG's total revenue from 2007 to 2022 (in billion U.S. dollars)

Characteristic	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

February 2023

More information

Region

Worldwide

Survey time period

2007 to 2022

Supplementary notes

This statistic was assembled from several editions of Novartis' annual report.
* With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015.
** During this year, eye care division Alcon was spun off and became an own company. Thus, Alcon's revenues are not included.

Open this statistic in...

French

Citation formats